Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $2.05 ($21K) on 2015-06-04, disclosed to the SEC on 2015-06-05.
Scheduled sale ($21k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.05 | 2,500 | $5K | 24.9% |
| 2 | $2.06 | 1,000 | $2K | 10.0% |
| 3 | $2.06 | 2,400 | $5K | 24.0% |
| 4 | $2.07 | 100 | $207 | 1.0% |
| 5 | $2.07 | 3,700 | $8K | 37.1% |
| 6 | $2.08 | 100 |
| $208 |
| 1.0% |
| 7 | $2.08 | 200 | $416 | 2.0% |
| Total | $2.06 avg | 10,000 | $21K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |